|
US2019144562A1
|
|
Antibodies, uses thereof and conjugates thereof
|
|
GB201708105D0
|
|
Antibodies, uses thereof and conjugates thereof
|
|
WO2017178828A1
|
|
Conjugates and conjugating reagents comprising a linker that includes at least two (-ch2-ch2-0-) units in a ring
|
|
GB201615725D0
|
|
Novel cytotoxic agents and conjugates thereof
|
|
GB201614162D0
|
|
Antibodies, uses thereof and conjugates thereof
|
|
GB201609866D0
|
|
Antibodies, uses thereof and conjugates thereof
|
|
GB201608936D0
|
|
Novel conjugates and novel conjugating reagents
|
|
GB201604808D0
|
|
Novel compounds and novel conjugating reagents
|
|
GB201603124D0
|
|
Novel compounds and conjugates
|
|
WO2016059377A1
|
|
Process for the conjugation of a peptide or protein with a reagent comprising a leaving group including a portion of peg
|
|
EP3220956A1
|
|
Conjugates and conjugating reagents
|
|
GB201517852D0
|
|
Novel compounds and conjugates
|
|
GB201509037D0
|
|
Novel conjugation process and reagents
|
|
GB201418984D0
|
|
Novel drug conjugates
|
|
GB201418986D0
|
|
Novel conjugates and novel conjugating reagents
|
|
GB201418989D0
|
|
Novel conjugation process and reagents
|
|
GB201418186D0
|
|
Novel conjugation process and reagents
|
|
CA2884359A1
|
|
Drug-protein conjugates
|
|
US2015290342A1
|
|
Drug-protein conjugates
|
|
CA2876365A1
|
|
Novel process for preparation of antibody conjugates and novel antibody conjugates
|
